The FDA has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Robert F. Kennedy, Jr. has never been afraid to challenge conventional wisdom-sometimes aligning with scientific consensus, ...

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

Two significant programs that invested in research on diabetes, dementia, obesity and kidney disease have ended since the ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

Chicken and eggs are high in phosphorus, a mineral certain people need in lower amounts. Find a list of foods here, ...

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...